198 related articles for article (PubMed ID: 31646996)
41. Tadalafil improves lean mass and endothelial function in nonobese men with mild ED/LUTS: in vivo and in vitro characterization.
Aversa A; Fittipaldi S; Francomano D; Bimonte VM; Greco EA; Crescioli C; Di Luigi L; Lenzi A; Migliaccio S
Endocrine; 2017 Jun; 56(3):639-648. PubMed ID: 28133708
[TBL] [Abstract][Full Text] [Related]
42. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
[TBL] [Abstract][Full Text] [Related]
43. The Effects of Korea Red Ginseng on Inflammatory Cytokines and Apoptosis in Rat Model with Chronic Nonbacterial Prostatitis.
Kang SW; Park JH; Seok H; Park HJ; Chung JH; Kim CJ; Kim YO; Han YR; Hong D; Kim YS; Kim SK
Biomed Res Int; 2019; 2019():2462561. PubMed ID: 30756082
[TBL] [Abstract][Full Text] [Related]
44. Effect of cernitin pollen-extract on experimental nonbacterial prostatitis in rats.
Kamijo T; Sato S; Kitamura T
Prostate; 2001 Oct; 49(2):122-31. PubMed ID: 11582591
[TBL] [Abstract][Full Text] [Related]
45. Anti-inflammatory and anti-hyperplastic effect of Bazhengsan in a male rat model of chronic nonbacterial prostatitis.
Xiong Y; Zhou L; Qiu X; Miao C
J Pharmacol Sci; 2019 Mar; 139(3):201-208. PubMed ID: 30773299
[TBL] [Abstract][Full Text] [Related]
46. Tadalafil - a therapeutic option in the management of BPH-LUTS.
Carson CC; Rosenberg M; Kissel J; Wong DG
Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
[TBL] [Abstract][Full Text] [Related]
47. Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
Bechara A; Casabe A; Rodriguez Baigorri G; Cobreros C
J Sex Med; 2014 Feb; 11(2):498-505. PubMed ID: 24224728
[TBL] [Abstract][Full Text] [Related]
48. Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis.
Wang Y; Bao Y; Liu J; Duan L; Cui Y
Low Urin Tract Symptoms; 2018 Jan; 10(1):84-92. PubMed ID: 29341503
[TBL] [Abstract][Full Text] [Related]
49. The Association of Phosphodiesterase 5 Inhibitor on Ischemia-Reperfusion Induced Kidney Injury in Rats.
Nam JK; Kim JH; Park SW; Chung MK
Urol J; 2020 Jan; 17(1):91-96. PubMed ID: 31912478
[TBL] [Abstract][Full Text] [Related]
50. Impact of postoperative phosphodiesterase type 5 inhibitor treatment on lower urinary tract symptoms after robot-assisted radical prostatectomy: a longitudinal study.
Honda M; Kawamoto B; Morizane S; Hikita K; Muraoka K; Sejima T; Takenaka A
Scand J Urol; 2017 Feb; 51(1):33-37. PubMed ID: 27841089
[TBL] [Abstract][Full Text] [Related]
51. Effects of Estrogen Receptor β Stimulation in a Rat Model of Non-Bacterial Prostatic Inflammation.
Mizoguchi S; Mori K; Wang Z; Liu T; Funahashi Y; Sato F; DeFranco DB; Yoshimura N; Mimata H
Prostate; 2017 May; 77(7):803-811. PubMed ID: 28181685
[TBL] [Abstract][Full Text] [Related]
52. Protective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia.
Zarifpour M; Nomiya M; Sawada N; Andersson KE
Prostate; 2015 Feb; 75(3):233-41. PubMed ID: 25327615
[TBL] [Abstract][Full Text] [Related]
53. Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
Roehrborn CG; Casabé A; Glina S; Sorsaburu S; Henneges C; Viktrup L
Int J Urol; 2015 Jun; 22(6):582-7. PubMed ID: 25827166
[TBL] [Abstract][Full Text] [Related]
54. Effect of tadalafil on male lower urinary tract symptoms: an integrated analysis of storage and voiding international prostate symptom subscores from four randomised controlled trials.
Chapple CR; Roehrborn CG; McVary K; Ilo D; Henneges C; Viktrup L
Eur Urol; 2015 Jan; 67(1):114-122. PubMed ID: 25301757
[TBL] [Abstract][Full Text] [Related]
55. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.
Egerdie RB; Auerbach S; Roehrborn CG; Costa P; Garza MS; Esler AL; Wong DG; Secrest RJ
J Sex Med; 2012 Jan; 9(1):271-81. PubMed ID: 21981682
[TBL] [Abstract][Full Text] [Related]
56. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
[TBL] [Abstract][Full Text] [Related]
57. The phosphodiesterase 5 inhibitor tadalafil has renoprotective effects in a rat model of chronic kidney disease.
Tomita N; Hotta Y; Naiki-Ito A; Hirano K; Kataoka T; Maeda Y; Takahashi S; Kimura K
Physiol Rep; 2020 Sep; 8(17):e14556. PubMed ID: 32889777
[TBL] [Abstract][Full Text] [Related]
58. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.
Andersson KE; de Groat WC; McVary KT; Lue TF; Maggi M; Roehrborn CG; Wyndaele JJ; Melby T; Viktrup L
Neurourol Urodyn; 2011 Mar; 30(3):292-301. PubMed ID: 21284024
[TBL] [Abstract][Full Text] [Related]
59. Tissue Kallikrein Protects Rat Prostate against the Inflammatory Damage in a Chronic Autoimmune Prostatitis Model via Restoring Endothelial Function in a Bradykinin Receptor B2-Dependent Way.
Zhang M; Lin D; Luo C; Wei P; Cui K; Chen Z
Oxid Med Cell Longev; 2022; 2022():1247806. PubMed ID: 35154561
[TBL] [Abstract][Full Text] [Related]
60. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.
Glina S; Roehrborn CG; Esen A; Plekhanov A; Sorsaburu S; Henneges C; Büttner H; Viktrup L
J Sex Med; 2015 Jan; 12(1):129-38. PubMed ID: 25353053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
